Skip to main content
. 2016 May 20;4(10):e12791. doi: 10.14814/phy2.12791

Figure 1.

Figure 1

Experimental procedures and effects of CB on body weight, tibial length, and PKA expression in Epac1KO. (A) Clenbuterol (CB) was administered once daily for 3 weeks via intraperitoneal injection (i.p.) at a dose of 2 mg/kg, dissolved in saline. Age‐matched control mice (Control) received an identical volume of saline only. (B and C), Body weight (BW; g) and tibial length (TL; mm) of Control and CB‐treated WT and Epac1KO. No significant difference in BW (B) or TL (C) was observed between Control and CB‐treated WT or Epac1KO (P = NS vs. Control by Tukey's test, n = 6 each). (D and E), PKA expression levels (total PKA‐catalytic units) in TA and SOL. No significant difference of PKA expression in either TA (D) or SOL (E) was observed between Control and CB‐treated WT or Epac1KO (P = NS vs. Control by Tukey's test, n = 6 each). The amount of expression in WT treated with saline (Control) was taken as 100% in each determination and representative immnunoblotting results are shown for total PKA catalytic units and GAPDH.